Retrospective Study of ImmunoFormulation for COVID-19

CompletedOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

July 2, 2020

Primary Completion Date

September 29, 2020

Study Completion Date

September 29, 2020

Conditions
Covid19
Interventions
DIETARY_SUPPLEMENT

ImmunoFormulation

The ImmunoFormulation consist of: transfer factors (oligo- and polypeptides from porcine spleen, ultrafiltered at \<10 kDa - Imuno TF®) 100 mg, 800 mg anti-inflammatory natural blend (Uncaria tomentosa, Endopleura uchi and Haematoccocus pluvialis - MiodesinTM), 60 mg zinc orotate, 48 mg selenium yeast (equivalent to 96 μg of Se), 20,000 IU cholecalciferol, 300 mg ascorbic acid, 480 mg ferulic acid, 90 mg resveratrol, 800 mg spirulina, 560 mg N-acetylcysteine, 610 mg glucosamine sulphate potassium chloride, and 400 mg maltodextrin-stabilized orthosilicic acid (equivalent to 6 mg of Si - SiliciuMax®).

Trial Locations (2)

08022

Clinic Bascoy, Barcelona

08037

Clínica Arvila Magna, Barcelona

All Listed Sponsors
lead

Fagron Iberica S.A.U.

INDUSTRY

NCT04666753 - Retrospective Study of ImmunoFormulation for COVID-19 | Biotech Hunter | Biotech Hunter